CoChat
Sign Up
Cited by 67Cancer Research and TreatmentsMicrobial Metabolic Engineering and BioproductionBacteriophages and microbial interactions

Genetically Engineered Microorganisms and Their Impact on Human Health

Open access
Mahdizade Ari, Marzie, Dadgar, Leila, Elahi, Zahra, Ghanavati, Roya, Taheri, Behrouz·2024·International Journal of Clinical Practice
DOI 10.1155/2024/6638269PMC PMC10944348
Open this paper in CoChat — free accountOpen PDF

Abstract

The emergence of antibiotic-resistant strains, the decreased effectiveness of conventional therapies, and the side effects have led researchers to seek a safer, more cost-effective, patient-friendly, and effective method that does not develop antibiotic resistance. With progress in synthetic biology and genetic engineering, genetically engineered microorganisms effective in treatment, prophylaxis, drug delivery, and diagnosis have been developed. The present study reviews the types of genetically engineered bacteria and phages, their impacts on diseases, cancer, and metabolic and inflammatory disorders, the biosynthesis of these modified strains, the route of administration, and their effects on the environment. We conclude that genetically engineered microorganisms can be considered promising candidates for adjunctive treatment of diseases and cancers.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2024/6638269

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 287

  1. [1]Liu Y. Feng J. Pan H. Zhang X. Zhang Y. Genetically engineered bacterium: principles, practices, and prospects Frontiers in Microbiology 2022 13 997587 10.3389/fmicb.2022.997587 PMC9606703 36312915 · DOI
  2. [2]Mukai T. Yoneji T. Yamada K. Fujita H. Nara S. Su’etsugu M. Overcoming the challenges of megabase-sized plasmid construction in Escherichia coli ACS Synthetic Biology 2020 9 6 1315 1327 10.1021/acssynbio.0c00008 32459960 · DOI
  3. [3]Waksman G. From conjugation to T4S systems in Gram-negative bacteria: a mechanistic biology perspective EMBO Reports 2019 20 2 e47012 10.15252/embr.201847012 2-s2.0-85059468855 PMC6362355 30602585 · DOI
  4. [4]Beumer K. J. Trautman J. K. Mukherjee K. Carroll D. Donor DNA utilization during gene targeting with zinc-finger nucleases G3 Genes Genomes Genetics 2013 3 4 657 664 10.1534/g3.112.005439 2-s2.0-84881060423 23550125 PMC3618352 · DOI
  5. [5]Hashimoto T. Hashimoto J. Teruya K. Biosynthesis of versipelostatin: identification of an enzyme-catalyzed [4+ 2]-cycloaddition required for macrocyclization of spirotetronate-containing polyketides Journal of the American Chemical Society 2015 137 2 572 575 10.1021/ja510711x 2-s2.0-84921516173 25551461 PMC4308742 · DOI
  6. [6]Li D. Tang Y. Lin J. Cai W. Methods for genetic transformation of filamentous fungi Microbial Cell Factories 2017 16 1 p. 168 10.1186/s12934-017-0785-7 2-s2.0-85030326638 PMC5627406 28974205 · DOI
  7. [7]Martin J. F. Nicolas G. Villanueva J. R. Chemical changes in the cell walls of conidia of Penicillium notatum during germination Canadian Journal of Microbiology 1973 19 7 789 796 10.1139/m73-128 2-s2.0-0015796527 4727802 · DOI
  8. [8]Citovsky V. Kozlovsky S. V. Lacroix B. Biological systems of the host cell involved in Agrobacterium infection Cellular Microbiology 2007 9 1 9 20 10.1111/j.1462-5822.2006.00830.x 2-s2.0-33845510957 17222189 · DOI
  9. [9]de Groot M. J. Bundock P. Hooykaas P. J. Beijersbergen A. G. Agrobacterium tumefaciens-mediated transformation of filamentous fungi Nature Biotechnology 1998 16 9 839 842 10.1038/nbt0998-839 2-s2.0-0031754395 9743116 · DOI
  10. [10]Ozeki K. Kyoya Fujii F. Hizume K. Kanda A. Hamachi M. Nunokawa Y. Transformation of intact Aspergillus Niger by electroporation Bioscience Biotechnology and Biochemistry 1994 58 12 2224 2227 10.1271/bbb.58.2224 2-s2.0-0028674950 7765715 · DOI
  11. [11]Gouka R. J. Punt P. J. van den Hondel C. A. M. J. J. Efficient production of secreted proteins by Aspergillus: progress, limitations and prospects Applied Microbiology and Biotechnology 1997 47 1 1 11 10.1007/s002530050880 2-s2.0-0031054007 9035405 · DOI
  12. [12]Sanford J. C. Smith F. D. Russell J. A. Optimizing the biolistic process for different biological applications Methods in Enzymology 1993 217 483 509 10.1016/0076-6879(93)17086-k 2-s2.0-0027251269 8474348 · DOI
  13. [13]Barcellos F. G. Fungaro M. H. Furlaneto M. C. Lejeune B. Pizzirani-Kleiner A. A. Lúcio de Azevedo J. Genetic analysis of Aspergillus nidulans unstable transformants obtained by the biolistic process Canadian Journal of Microbiology 1998 44 12 1137 1141 10.1139/w98-213 10347861 · DOI
  14. [14]Herzog R. Daniell H. Singh N. Lemke P. A comparative study on the transformation of Aspergillus nidulans by microprojectile bombardment of conidia and a more conventional procedure using protoplasts treated with polyethyleneglycol Applied Microbiology and Biotechnology 1996 45 3 333 337 10.1007/s002530050692 2-s2.0-0029948244 · DOI
  15. [15]Coconi-Linares N. Magaña-Ortíz D. Guzmán-Ortiz D. A. Fernández F. Loske A. M. Gómez-Lim M. A. High-yield production of manganese peroxidase, lignin peroxidase, and versatile peroxidase in Phanerochaete chrysosporium Applied Microbiology and Biotechnology 2014 98 22 9283 9294 10.1007/s00253-014-6105-9 2-s2.0-84925489180 25269601 · DOI
  16. [16]Ramesh N. Ge Y. Ennist D. L. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer Clinical Cancer Research 2006 12 1 305 313 10.1158/1078-0432.ccr-05-1059 2-s2.0-31544478298 16397056 · DOI
  17. [18]Kaufman H. L. Kohlhapp F. J. Zloza A. Oncolytic viruses: a new class of immunotherapy drugs Nature Reviews Drug Discovery 2015 14 9 642 662 10.1038/nrd4663 2-s2.0-84940824279 26323545 PMC7097180 · DOI
  18. [19]Parker J. N. Pfister L. A. Quenelle D. Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates Vaccine 2006 24 10 1644 1652 10.1016/j.vaccine.2005.09.051 2-s2.0-32544431705 16243413 · DOI
  19. [20]Gouka R. J. Punt P. J. van den Hondel C. A. Efficient production of secreted proteins by Aspergillus: progress, limitations and prospects Applied Microbiology and Biotechnology 1997 47 1 1 11 10.1007/s002530050880 2-s2.0-0031054007 9035405 · DOI
  20. [21]Citovsky V. Kozlovsky S. V. Lacroix B. Biological systems of the host cell involved in Agrobacterium infection Cellular Microbiology 2007 9 1 9 20 10.1111/j.1462-5822.2006.00830.x 2-s2.0-33845510957 17222189 · DOI
  21. [22]Gouka R. Punt P. Van Den Hondel C. Efficient production of secreted proteins by Aspergillus: progress, limitations and prospects Applied Microbiology and Biotechnology 1997 47 1 11 10.1007/s002530050880 2-s2.0-0031054007 9035405 · DOI
  22. [23]Sanford J. Smith F. Russell J. Optimizing the biolistic process for different biological applications Methods in Enzymology 1993 217 483 509 10.1016/0076-6879(93)17086-k 2-s2.0-0027251269 8474348 · DOI
  23. [24]Magaña-Ortíz D. Coconi-Linares N. Ortiz-Vazquez E. Fernández F. Loske A. M. Gómez-Lim M. A. A novel and highly efficient method for genetic transformation of fungi employing shock waves Fungal Genetics and Biology 2013 56 9 16 10.1016/j.fgb.2013.03.008 2-s2.0-84879502547 23583899 · DOI
  24. [25]Ogden J. A. Tóth-Kischkat A. Schultheiss R. Principles of shock wave therapy Clinical Orthopaedics and Related Research 2001 387 8 17 10.1097/00003086-200106000-00003 2-s2.0-0034989722 11400898 · DOI
  25. [26]Mateu M. G. Virus engineering: functionalization and stabilization Protein Engineering Design and Selection 2011 24 1-2 53 63 10.1093/protein/gzq069 2-s2.0-78650459403 20923881 · DOI
  26. [27]Ogden J. A. Tóth-Kischkat A. Schultheiss R. Principles of shock wave therapy Clinical Orthopaedics and Related Research 2001 387 387 8 17 10.1097/00003086-200106000-00003 2-s2.0-0034989722 11400898 · DOI
  27. [28]Gorlach K. Problems in the introduction of genetically engineered microorganisms into the environment Acta Microbiologica Polonica 1994 43 2 121 131 7530892
  28. [29]Smyth S. Gusta M. Belcher K. Phillips P. Castle D. Changes in herbicide use after adoption of HR canola in western Canada Weed Technology 2011 25 3 492 500 10.1614/wt-d-10-00164.1 2-s2.0-79961022092 · DOI
  29. [30]Thomas C. D. Cameron A. Green R. E. Extinction risk from climate change Nature 2004 427 6970 145 148 10.1038/nature02121 2-s2.0-1542329839 14712274 · DOI
  30. [31]Rafeeq H. Afsheen N. Rafique S. Genetically engineered microorganisms for environmental remediation Chemosphere 2023 310 136751 10.1016/j.chemosphere.2022.136751 36209847 · DOI · Paper page
  31. [33]Urgun-Demirtas M. Stark B. Pagilla K. Use of genetically engineered microorganisms (GEMs) for the bioremediation of contaminants Critical Reviews in Biotechnology 2006 26 3 145 164 10.1080/07388550600842794 2-s2.0-33750009593 16923532 · DOI
  32. [34]Brookes G. Barfoot P. Environmental impacts of genetically modified (GM) crop use 1996-2018: impacts on pesticide use and carbon emissions Genetically Modified Crops and Food 2020 11 4 215 241 10.1080/21645698.2020.1773198 PMC7518756 32706316 · DOI
  33. [36]van Elsas J. D. Trevors J. T. Environmental risks and fate of genetically engineered microorganisms in soil Journal of Environmental Science and Health Part A: Environmental Science and Engineering and Toxicology 1991 26 6 981 1001 10.1080/10934529109375679 2-s2.0-0026205930 · DOI
  34. [37]Council N. R. The Impact of Genetically Engineered Crops on Farm Sustainability in the United States 2010 Washington, DC, USA The National Academies Press
  35. [38]Keese P. Risks from GMOs due to horizontal gene transfer Environmental Biosafety Research 2008 7 3 123 149 10.1051/ebr:2008014 2-s2.0-52749091471 18801324 · DOI
  36. [39]Paul D. Pandey G. Jain R. K. Suicidal genetically engineered microorganisms for bioremediation: need and perspectives BioEssays 2005 27 5 563 573 10.1002/bies.20220 2-s2.0-18744369064 15832375 · DOI
  37. [40]Sharma P. Singh S. P. Iqbal H. M. N. Parra-Saldivar R. Varjani S. Tong Y. W. Genetic modifications associated with sustainability aspects for sustainable developments Bioengineered 2022 13 4 9509 9521 10.1080/21655979.2022.2061146 PMC9161841 35389819 · DOI
  38. [41]Potdar A. Business initiatives for conservation and enhancement of biodiversity Journal of Ecosystem and Ecography 2012 01 S1 10.4172/2157-7625.s1.009 · DOI
  39. [43]Ma J. K. Drake P. M. Christou P. The production of recombinant pharmaceutical proteins in plants Nature Reviews Genetics 2003 4 10 794 805 10.1038/nrg1177 2-s2.0-0141706699 14526375 · DOI
  40. [44]Davison J. Genetic exchange between bacteria in the environment Plasmid 1999 42 2 73 91 10.1006/plas.1999.1421 2-s2.0-0032870855 10489325 · DOI
  41. [45]Moe-Behrens G. H. Davis R. Haynes K. A. Preparing synthetic biology for the world Frontiers in Microbiology 2013 4 p. 5 10.3389/fmicb.2013.00005 2-s2.0-84875851718 PMC3554958 23355834 · DOI
  42. [46]Jones R. A. C. Global plant virus disease pandemics and epidemics Plants 2021 10 2 p. 233 10.3390/plants10020233 PMC7911862 33504044 · DOI
  43. [47]Materatski P. Jones S. Patanita M. A bipartite geminivirus with a highly divergent genomic organization identified in olive trees may represent a novel evolutionary direction in the family geminiviridae Viruses 2021 13 10 p. 2035 10.3390/v13102035 PMC8540022 34696465 · DOI
  44. [48]Varanda C. Félix M. R. Campos M. D. Materatski P. An overview of the application of viruses to biotechnology Viruses 2021 13 10 p. 2073 10.3390/v13102073 PMC8541484 34696503 · DOI
  45. [49]Turner J. S. O’Halloran J. A. Kalaidina E. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses Nature 2021 596 7870 109 113 10.1038/s41586-021-03738-2 34182569 PMC8935394 · DOI · Paper page
  46. [51]Varanda C. M. Materatski P. Campos M. D. Clara M. I. E. Nolasco G. Félix M. D. R. Olive mild mosaic virus coat protein and P6 are suppressors of RNA silencing, and their silencing confers resistance against OMMV Viruses 2018 10 8 p. 416 10.3390/v10080416 2-s2.0-85051500397 PMC6115721 30096871 · DOI
  47. [52]Zaidi S. S. Mansoor S. Viral vectors for plant genome engineering Frontiers in Plant Science 2017 8 p. 539 10.3389/fpls.2017.00539 2-s2.0-85017954149 PMC5386974 28443125 · DOI
  48. [54]Pijlman G. P. Grose C. Hick T. A. H. Relocation of the attTn7 transgene insertion site in bacmid DNA enhances baculovirus genome stability and recombinant protein expression in insect cells Viruses 2020 12 12 p. 1448 10.3390/v12121448 PMC7765880 33339324 · DOI
  49. [55]Hsu C. W. Chang M. H. Chang H. W. Wu T. Y. Chang Y. C. Parenterally administered porcine epidemic diarrhea virus-like particle-based vaccine formulated with CCL25/28 chemokines induces systemic and mucosal immune protectivity in pigs Viruses 2020 12 10 p. 1122 10.3390/v12101122 PMC7600258 33023277 · DOI
  50. [56]Maeda K. Kikuchi T. Kasajima I. Virus-induced flowering by apple latent spherical virus vector: effective use to accelerate breeding of grapevine Viruses 2020 12 1 p. 70 10.3390/v12010070 PMC7019355 31936111 · DOI
  51. [57]Fukuhara H. Ino Y. Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn Cancer Science 2016 107 10 1373 1379 10.1111/cas.13027 2-s2.0-84987814994 27486853 PMC5084676 · DOI
  52. [58]Kim J. H. Oh J. Y. Park B. H. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF Molecular Therapy 2006 14 3 361 370 10.1016/j.ymthe.2006.05.008 2-s2.0-33746916507 16905462 · DOI
  53. [60]Parato K. A. Breitbach C. J. Le Boeuf F. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers Molecular Therapy 2012 20 4 749 758 10.1038/mt.2011.276 2-s2.0-84859443203 22186794 PMC3321594 · DOI
  54. [61]Zhang K. Tang Y. Chen Q. Liu Y. The screening of therapeutic peptides for anti-inflammation through phage display technology International Journal of Molecular Sciences 2022 23 15 p. 8554 10.3390/ijms23158554 PMC9368796 35955688 · DOI
  55. [62]Chen Y. Batra H. Dong J. Chen C. Rao V. B. Tao P. Genetic engineering of bacteriophages against infectious diseases Frontiers in Microbiology 2019 10 p. 954 10.3389/fmicb.2019.00954 2-s2.0-85068656018 PMC6509161 31130936 · DOI
  56. [63]Gibb B. Hyman P. Schneider C. L. The many applications of engineered bacteriophages-an overview Pharmaceuticals 2021 14 7 p. 634 10.3390/ph14070634 PMC8308837 34208847 · DOI
  57. [64]Weynberg K. D. Jaschke P. R. Building better bacteriophage with biofoundries to combat antibiotic-resistant bacteria Phage 2020 1 1 23 26 10.1089/phage.2019.0005 36147618 PMC9041446 · DOI
  58. [65]Łobocka M. Dąbrowska K. Górski A. Engineered bacteriophage therapeutics: rationale, challenges and future BioDrugs 2021 35 3 255 280 10.1007/s40259-021-00480-z 33881767 PMC8084836 · DOI
  59. [66]Principi N. Silvestri E. Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections Frontiers in Pharmacology 2019 10 p. 513 10.3389/fphar.2019.00513 2-s2.0-85068838343 PMC6517696 31139086 · DOI
  60. [67]Shreiner A. B. Kao J. Y. Young V. B. The gut microbiome in health and in disease Current Opinion in Gastroenterology 2015 31 1 69 75 10.1097/mog.0000000000000139 2-s2.0-84917679751 25394236 PMC4290017 · DOI
  61. [69]Hsu B. B. Gibson T. E. Yeliseyev V. Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model Cell Host & Microbe 2019 25 6 803 814.e5 10.1016/j.chom.2019.05.001 2-s2.0-85066807634 31175044 PMC6579560 · DOI · Paper page
  62. [70]Lu T. K. Collins J. J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy Proceedings of the National Academy of Sciences of the United States of America 2009 106 12 4629 4634 10.1073/pnas.0800442106 2-s2.0-63849290890 19255432 PMC2649960 · DOI
  63. [71]Masuda Y. Kawabata S. Uedoi T. Honjoh K.-I. Miyamoto T. Tyne D. V. Construction of leaderless-bacteriocin-producing bacteriophage targeting E. coli and neighboring gram-positive pathogens Microbiology Spectrum 2021 9 1 p. 14121 10.1128/spectrum.00141-21 PMC8552711 34259542 · DOI
  64. [72]Krom R. J. Bhargava P. Lobritz M. A. Collins J. J. Engineered phagemids for nonlytic, targeted antibacterial therapies Nano Letters 2015 15 7 4808 4813 10.1021/acs.nanolett.5b01943 2-s2.0-84936804003 26044909 · DOI
  65. [73]Cass J. Barnard A. Fairhead H. Engineered bacteriophage as a delivery vehicle for antibacterial protein, SASP Pharmaceuticals 2021 14 10 p. 1038 10.3390/ph14101038 PMC8538823 34681262 · DOI
  66. [74]Moradpour Z. Sepehrizadeh Z. Rahbarizadeh F. Ghasemian A. Yazdi M. T. Shahverdi A. R. Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli FEMS Microbiology Letters 2009 296 1 67 71 10.1111/j.1574-6968.2009.01620.x 2-s2.0-67149123645 19459966 · DOI
  67. [75]Hsu B. B. Way J. C. Silver P. A. Stable neutralization of a virulence factor in bacteria using temperate phage in the mammalian gut mSystems 2020 5 1 13 20 10.1128/msystems.00013-20 PMC6989128 31992629 · DOI
  68. [76]Kiga K. Tan X. E. Ibarra-Chávez R. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria Nature Communications 2020 11 1 p. 2934 10.1038/s41467-020-16731-6 PMC7287087 32523110 · DOI
  69. [77]Lemon D. J. Kay M. K. Titus J. K. Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018 Journal of Microbiology 2019 57 6 532 538 10.1007/s12275-019-8686-6 2-s2.0-85066323992 31054139 · DOI
  70. [78]Citorik R. J. Mimee M. Lu T. K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases Nature Biotechnology 2014 32 11 1141 1145 10.1038/nbt.3011 2-s2.0-84983208863 PMC4237163 25240928 · DOI · Paper page
  71. [79]Hagens S. Blasi U. Genetically modified filamentous phage as bactericidal agents: a pilot study Letters in Applied Microbiology 2003 37 4 318 323 10.1046/j.1472-765x.2003.01400.x 2-s2.0-0141762466 12969496 · DOI
  72. [80]Westwater C. Kasman L. M. Schofield D. A. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections Antimicrobial Agents and Chemotherapy 2003 47 4 1301 1307 10.1128/AAC.47.4.1301-1307.2003 2-s2.0-0037379524 12654662 PMC152521 · DOI
  73. [81]Lu T. K. Collins J. J. Dispersing biofilms with engineered enzymatic bacteriophage Proceedings of the National Academy of Sciences of the United States of America 2007 104 27 11197 11202 10.1073/pnas.0704624104 2-s2.0-34547448587 17592147 PMC1899193 · DOI · Paper page
  74. [82]Yosef I. Manor M. Kiro R. Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria Proceedings of the National Academy of Sciences of the United States of America 2015 112 23 7267 7272 10.1073/pnas.1500107112 2-s2.0-84931291929 26060300 PMC4466736 · DOI
  75. [83]Park J. Y. Moon B. Y. Park J. W. Thornton J. A. Park Y. H. Seo K. S. Genetic engineering of a temperate phage-based delivery system for CRISPR/Cas9 antimicrobials against Staphylococcus aureus Scientific Reports 2017 7 1 44929 10.1038/srep44929 2-s2.0-85016051955 PMC5359561 28322317 · DOI
  76. [84]Lam K. N. Spanogiannopoulos P. Soto-Perez P. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome Cell Reports 2021 37 5 109930 10.1016/j.celrep.2021.109930 PMC8591988 34731631 · DOI
  77. [85]Soria L. R. Brunetti-Pierri N. Targeting autophagy for therapy of hyperammonemia Autophagy 2018 14 7 1273 1275 10.1080/15548627.2018.1444312 2-s2.0-85050513816 30035657 PMC6103655 · DOI
  78. [86]Barnard A. M. L. Fairhead H. I. M. A commentary on the development of engineered phage as therapeutics Drug Discovery Today 2021 26 9 2095 2098 10.1016/j.drudis.2021.06.013 34237459 · DOI
  79. [87]Ross A. Ward S. Hyman P. More is better: selecting for broad host range bacteriophages Frontiers in Microbiology 2016 7 p. 1352 10.3389/fmicb.2016.01352 2-s2.0-84992741122 PMC5014875 27660623 · DOI
  80. [88]Abedon S. T. Danis-Wlodarczyk K. M. Wozniak D. J. Phage cocktail development for bacteriophage therapy: toward improving spectrum of activity breadth and depth Pharmaceuticals 2021 14 10 p. 1019 10.3390/ph14101019 PMC8541335 34681243 · DOI
  81. [89]Yehl K. Lemire S. Yang A. C. Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis Cell 2019 179 2 459 469.e9 10.1016/j.cell.2019.09.015 2-s2.0-85072541260 31585083 PMC6924272 · DOI
  82. [90]Lu T. K. Collins J. J. Dispersing biofilms with engineered enzymatic bacteriophage Proceedings of the National Academy of Sciences 2007 104 27 11197 11202 10.1073/pnas.0704624104 2-s2.0-34547448587 PMC1899193 17592147 · DOI · Paper page
  83. [91]Bar H. Yacoby I. Benhar I. Killing cancer cells by targeted drug-carrying phage nanomedicines BMC Biotechnology 2008 8 1 37 114 10.1186/1472-6750-8-37 2-s2.0-42449132988 18387177 PMC2323368 · DOI · Paper page
  84. [92]Anand P. O’Neil A. Lin E. Douglas T. Holford M. Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers Scientific Reports 2015 5 1 12497 10.1038/srep12497 2-s2.0-84938524946 PMC4522602 26234920 · DOI
  85. [93]Jin M. Chen J. Zhao X. An engineered λ phage enables enhanced and strain-specific killing of enterohemorrhagic Escherichia coli Microbiology Spectrum 2022 10 4 p. 127122 10.1128/spectrum.01271-22 PMC9431524 35876591 · DOI
  86. [94]Dedrick R. M. Guerrero-Bustamante C. A. Garlena R. A. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus Nature Medicine 2019 25 5 730 733 10.1038/s41591-019-0437-z 2-s2.0-85065592443 PMC6557439 31068712 · DOI
  87. [95]Selle K. Fletcher J. R. Tuson H. In vivo targeting of Clostridioides difficile using phage-delivered CRISPR-Cas3 antimicrobials mBio 2020 11 2 p. 19 10.1128/mbio.00019-20 PMC7064742 32156803 · DOI
  88. [96]Vaidya J. G. Rabba A. S. Fungi in folk medicine Mycologist 1993 7 3 131 133 10.1016/s0269-915x(09)80073-6 2-s2.0-3543111065 · DOI
  89. [97]Khan A. A. Bacha N. Ahmad B. Lutfullah G. Farooq U. Cox R. J. Fungi as chemical industries and genetic engineering for the production of biologically active secondary metabolites Asian Pacific Journal of Tropical Biomedicine 2014 4 11 859 870 10.12980/apjtb.4.2014apjtb-2014-0230 2-s2.0-84922713680 · DOI
  90. [98]Meyer V. Genetic engineering of filamentous fungi--progress, obstacles and future trends Biotechnology Advances 2008 26 2 177 185 10.1016/j.biotechadv.2007.12.001 2-s2.0-38349002470 18201856 · DOI
  91. [99]Ruiz-Díez B. Strategies for the transformation of filamentous fungi Journal of Applied Microbiology 2002 92 2 189 195 10.1046/j.1365-2672.2002.01516.x 2-s2.0-0036162014 11849345 · DOI
  92. [100]Gouka R. J. Gerk C. Hooykaas P. J. Transformation of Aspergillus awamori by Agrobacterium tumefaciens–mediated homologous recombination Nature Biotechnology 1999 17 6 598 601 10.1038/9915 2-s2.0-0033017215 10385327 · DOI
  93. [101]Zhao H. Lovett B. Fang W. Genetically engineering entomopathogenic fungi Advances in Genetics 2016 94 137 163 10.1016/bs.adgen.2015.11.001 2-s2.0-84971413840 27131325 · DOI
  94. [102]Wang Q. Zhong C. Xiao H. Genetic engineering of filamentous fungi for efficient protein expression and secretion Frontiers in Bioengineering and Biotechnology 2020 8 p. 293 10.3389/fbioe.2020.00293 PMC7156587 32322579 · DOI
  95. [103]Son Y. E. Park H. S. Genetic manipulation and transformation methods for Aspergillus spp Mycobiology 2021 49 2 95 104 10.1080/12298093.2020.1838115 37970179 PMC10635212 · DOI
  96. [104]van den Hombergh J. P. van de Vondervoort P. J. Fraissinet-Tachet L. Visser J. Aspergillus as a host for heterologous protein production: the problem of proteases Trends in Biotechnology 1997 15 7 256 263 10.1016/s0167-7799(97)01020-2 2-s2.0-0030841912 9237405 · DOI
  97. [105]Niu J. Arentshorst M. Seelinger F. Ram A. F. Ouedraogo J. P. A set of isogenic auxotrophic strains for constructing multiple gene deletion mutants and parasexual crossings in Aspergillus Niger Archives of Microbiology 2016 198 9 861 868 10.1007/s00203-016-1240-6 2-s2.0-84973131401 27251039 PMC5040738 · DOI
  98. [106]Akin D. Sturgis J. Ragheb K. Bacteria-mediated delivery of nanoparticles and cargo into cells Nature Nanotechnology 2007 2 7 441 449 10.1038/nnano.2007.149 2-s2.0-34447118226 18654330 · DOI
  99. [107]Pronk J. T. Auxotrophic yeast strains in fundamental and applied research Applied and Environmental Microbiology 2002 68 5 2095 2100 10.1128/aem.68.5.2095-2100.2002 2-s2.0-0036249933 11976076 PMC127579 · DOI
  100. [108]Ghanavati R. Akbari A. Mohammadi F. Lactobacillus species inhibitory effect on colorectal cancer progression through modulating the Wnt/β-catenin signaling pathway Molecular and Cellular Biochemistry 2020 470 1-2 1 13 10.1007/s11010-020-03740-8 32419125 · DOI
  101. [109]Aggarwal N. Breedon A. M. E. Davis C. M. Hwang I. Y. Chang M. W. Engineering probiotics for therapeutic applications: recent examples and translational outlook Current Opinion in Biotechnology 2020 65 171 179 10.1016/j.copbio.2020.02.016 32304955 · DOI
  102. [110]Sedighi M. Zahedi Bialvaei A. Hamblin M. R. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities Cancer Medicine 2019 8 6 3167 3181 10.1002/cam4.2148 2-s2.0-85067200315 30950210 PMC6558487 · DOI
  103. [111]Parisa A. Roya G. Mahdi R. Shabnam R. Maryam E. Malihe T. Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis PLoS One 2020 15 5 232930 10.1371/journal.pone.0232930 PMC7219778 32401801 · DOI
  104. [112]Biller B. J. D. S. C.-I. C. I. W. S. Vail D. M. Withrow & MacEwen’s Small Animal Clinical Oncology 2007 4th Saint Louis, MO, USA W.B. Saunders
  105. [113]Ma J. Lyu Y. Liu X. Engineered probiotics Microbial Cell Factories 2022 21 1 p. 72 10.1186/s12934-022-01799-0 PMC9044805 35477497 · DOI
  106. [114]Moghimipour E. Abedishirehjin S. Baghbadorani M. A. Handali S. Bacteria and Archaea: a new era of cancer therapy Journal of Controlled Release 2021 338 1 7 10.1016/j.jconrel.2021.08.019 34391833 · DOI
  107. [115]Mao N. Cubillos-Ruiz A. Cameron D. E. Collins J. J. Probiotic strains detect and suppress cholera in mice Science Translational Medicine 2018 10 445 2586 10.1126/scitranslmed.aao2586 2-s2.0-85048421102 PMC7821980 29899022 · DOI
  108. [116]Lubkowicz D. Ho C. L. Hwang I. Y. Yew W. S. Lee Y. S. Chang M. W. Reprogramming probiotic Lactobacillus reuteri as a biosensor for Staphylococcus aureus derived AIP-I detection ACS Synthetic Biology 2018 7 5 1229 1237 10.1021/acssynbio.8b00063 2-s2.0-85047375452 29652493 · DOI
  109. [117]Geldart K. G. Kommineni S. Forbes M. Engineered E. coli Nissle 1917 for the reduction of vancomycin‐resistant Enterococcus in the intestinal tract Bioengineering and translational medicine 2018 3 3 197 208 10.1002/btm2.10107 30377660 PMC6195901 · DOI · Paper page
  110. [118]Chen K. Zhu Y. Zhang Y. A probiotic yeast-based immunotherapy against Clostridioides difficile infection Science Translational Medicine 2020 12 567 eaax4905 10.1126/scitranslmed.aax4905 PMC7692727 33115949 · DOI
  111. [119]Drolia R. Amalaradjou M. A. Ryan V. Receptor-targeted engineered probiotics mitigate lethal Listeria infection Nature Communications 2020 11 1 p. 6344 10.1038/s41467-020-20200-5 PMC7732855 33311493 · DOI
  112. [121]Gurbatri C. R. Lia I. Vincent R. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies Science Translational Medicine 2020 12 530 eaax0876 10.1126/scitranslmed.aax0876 PMC7685004 32051224 · DOI · Paper page
  113. [122]Pan H. Li L. Pang G. Engineered NIR light-responsive bacteria as anti-tumor agent for targeted and precise cancer therapy Chemical Engineering Journal 2021 426 130842 10.1016/j.cej.2021.130842 · DOI
  114. [123]He L. Yang H. Tang J. Intestinal probiotics E. coli Nissle 1917 as a targeted vehicle for delivery of p53 and Tum-5 to solid tumors for cancer therapy Journal of Biological Engineering 2019 13 1 13 10.1186/s13036-019-0189-9 2-s2.0-85068412025 31297149 PMC6599283 · DOI
  115. [125]Bermúdez-Humarán L. G. Langella P. Cortes-Perez N. G. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production Infection and Immunity 2003 71 4 1887 1896 10.1128/iai.71.4.1887-1896.2003 2-s2.0-3042659382 12654805 PMC152106 · DOI
  116. [126]Wei C. Xun A. Y. Wei X. X. Bifidobacteria expressing tumstatin protein for antitumor therapy in tumor-bearing mice Technology in Cancer Research and Treatment 2016 15 3 498 508 10.1177/1533034615581977 2-s2.0-84966641629 25969440 · DOI · Paper page
  117. [127]Yazawa K. Fujimori M. Amano J. Kano Y. Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors Cancer Gene Therapy 2000 7 2 269 274 10.1038/sj.cgt.7700122 2-s2.0-0034032620 10770636 · DOI
  118. [128]Durrer K. E. Allen M. S. Hunt von Herbing I. Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU PLoS One 2017 12 5 176286 10.1371/journal.pone.0176286 2-s2.0-85019912671 PMC5435137 28520731 · DOI
  119. [129]Yan X. Liu X. Y. Zhang D. Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis Cellular and Molecular Immunology 2021 18 10 2344 2357 10.1038/s41423-021-00760-2 34480146 PMC8484604 · DOI
  120. [130]Cui M. Pang G. Zhang T. Optotheranostic nanosystem with phone visual diagnosis and optogenetic microbial therapy for ulcerative colitis at-home care ACS Nano 2021 15 4 7040 7052 10.1021/acsnano.1c00135 33819424 · DOI
  121. [131]Ma J. Li C. Wang J. Gu J. Genetically engineered Escherichia coli Nissle 1917 secreting GLP-1 analog exhibits potential antiobesity effect in high-fat diet-induced obesity mice Obesity 2020 28 2 315 322 10.1002/oby.22700 31970910 · DOI
  122. [132]Duan F. F. Liu J. H. March J. C. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes Diabetes 2015 64 5 1794 1803 10.2337/db14-0635 2-s2.0-84964694501 25626737 PMC4407861 · DOI · Paper page
  123. [133]Puurunen M. K. Vockley J. Searle S. L. Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study Nature Metabolism 2021 3 8 1125 1132 10.1038/s42255-021-00430-7 34294923 · DOI
  124. [134]Zheng R. Li Y. Wang L. CRISPR/Cas9–mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1 Kidney International 2020 98 4 947 957 10.1016/j.kint.2020.04.049 32464217 · DOI
  125. [135]Kurtz C. B. Millet Y. A. Puurunen M. K. An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Science Translational Medicine 2019 11 475 eaau7975 10.1126/scitranslmed.aau7975 2-s2.0-85060169680 30651324 · DOI · Paper page
  126. [136]Daeffler K. N. Galley J. D. Sheth R. U. Engineering bacterial thiosulfate and tetrathionate sensors for detecting gut inflammation Molecular Systems Biology 2017 13 4 p. 923 10.15252/msb.20167416 2-s2.0-85018358793 28373240 PMC5408782 · DOI
  127. [137]Kotula J. W. Kerns S. J. Shaket L. A. Programmable bacteria detect and record an environmental signal in the mammalian gut Proceedings of the National Academy of Sciences of the United States of America 2014 111 13 4838 4843 10.1073/pnas.1321321111 2-s2.0-84897482912 24639514 PMC3977281 · DOI
  128. [138]McKay R. Ghodasra M. Schardt J. A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: toward applications for Crohn’s disease Bioengineering and translational medicine 2018 3 3 209 221 10.1002/btm2.10113 30377661 PMC6195910 · DOI
  129. [139]Praveschotinunt P. Duraj-Thatte A. M. Gelfat I. Bahl F. Chou D. B. Joshi N. S. Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut Nature Communications 2019 10 1 p. 5580 10.1038/s41467-019-13336-6 PMC6898321 31811125 · DOI
  130. [140]Li Z. Wang Y. Liu J. Chemically and biologically engineered bacteria-based delivery systems for emerging diagnosis and advanced therapy Advanced Materials 2021 33 38 e2102580 10.1002/adma.202102580 34347325 · DOI
  131. [141]Scott B. M. Gutierrez-Vazquez C. Sanmarco L. M. Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease Nature Medicine 2021 27 7 1212 1222 10.1038/s41591-021-01390-x 34183837 · DOI
  132. [142]Paton A. W. Jennings M. P. Morona R. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea Gastroenterology 2005 128 5 1219 1228 10.1053/j.gastro.2005.01.050 2-s2.0-19044375218 15887106 · DOI
  133. [143]Jayaraman P. Holowko M. B. Yeoh J. W. Lim S. Poh C. L. Repurposing a two-component system-based biosensor for the killing of Vibrio cholerae ACS Synthetic Biology 2017 6 7 1403 1415 10.1021/acssynbio.7b00058 2-s2.0-85025145415 28441472 · DOI
  134. [144]Lu J. Zhu X. Zhang C. Lu F. Lu Z. Lu Y. Co-expression of alcohol dehydrogenase and aldehyde dehydrogenase in Bacillus subtilis for alcohol detoxification Food and Chemical Toxicology 2020 135 110890 10.1016/j.fct.2019.110890 2-s2.0-85073812212 31628963 · DOI
  135. [145]Hamady Z. Z. Scott N. Farrar M. D. Treatment of colitis with a commensal gut bacterium engineered to secrete human tgf-β1 under the control of dietary xylan Inflammatory Bowel Diseases 2011 17 9 1925 1935 10.1002/ibd.21565 2-s2.0-80051504591 21830271 · DOI
  136. [148]Zheng J. H. Nguyen V. H. Jiang S. N. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin Science Translational Medicine 2017 9 376 p. 9537 10.1126/scitranslmed.aak9537 2-s2.0-85012934976 28179508 · DOI · Paper page
  137. [149]Castagliuolo I. Beggiao E. Brun P. Engineered E. coli delivers therapeutic genes to the colonic mucosa Gene Therapy 2005 12 13 1070 1078 10.1038/sj.gt.3302493 2-s2.0-21744447859 15815705 · DOI
  138. [150]Piraner D. I. Abedi M. H. Moser B. A. Lee-Gosselin A. Shapiro M. G. Tunable thermal bioswitches for in vivo control of microbial therapeutics Nature Chemical Biology 2017 13 1 75 80 10.1038/nchembio.2233 2-s2.0-85048523959 27842069 · DOI
  139. [151]Courbet A. Endy D. Renard E. Molina F. Bonnet J. Detection of pathological biomarkers in human clinical samples via amplifying genetic switches and logic gates Science Translational Medicine 2015 7 289 p. 289ra83 10.1126/scitranslmed.aaa3601 2-s2.0-84930163953 26019219 · DOI
  140. [152]Piñero-Lambea C. Bodelón G. Fernández-Periáñez R. Cuesta A. M. Álvarez-Vallina L. Fernández L. Programming controlled adhesion of E. coli to target surfaces, cells, and tumors with synthetic adhesins ACS Synthetic Biology 2015 4 4 463 473 10.1021/sb500252a 2-s2.0-84928157072 25045780 PMC4410913 · DOI
  141. [153]Yoon W. Park Y. C. Kim J. Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma European Journal of Cancer 2017 70 48 61 10.1016/j.ejca.2016.10.010 2-s2.0-84996619330 27883926 · DOI
  142. [154]Gong S. Yan Z. Liu Z. Intestinal microbiota mediates the susceptibility to polymicrobial sepsis-induced liver injury by granisetron generation in mice Hepatology 2019 69 4 1751 1767 10.1002/hep.30361 2-s2.0-85062513070 30506577 · DOI · Paper page
  143. [155]Dunne M. al-Ramadi B. K. Barthold S. W. Flavell R. A. Fikrig E. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis Infection and Immunity 1995 63 4 1611 1614 10.1128/iai.63.4.1611-1614.1995 7890431 PMC173199 · DOI
  144. [156]Giomarelli B. Provvedi R. Meacci F. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1 AIDS 2002 16 10 1351 1356 10.1097/00002030-200207050-00006 2-s2.0-0037024754 12131211 · DOI
  145. [157]Focareta A. Paton J. C. Morona R. Cook J. Paton A. W. A recombinant probiotic for treatment and prevention of cholera Gastroenterology 2006 130 6 1688 1695 10.1053/j.gastro.2006.02.005 2-s2.0-33646352688 16697733 · DOI
  146. [158]Camacho E. M. Mesa-Pereira B. Medina C. Flores A. Santero E. Engineering Salmonella as intracellular factory for effective killing of tumour cells Scientific Reports 2016 6 1 30591 10.1038/srep30591 2-s2.0-84979879814 PMC4964584 27464652 · DOI
  147. [159]Sehrawat N. Yadav M. Singh M. Kumar V. Sharma V. R. Sharma A. K. Probiotics in microbiome ecological balance providing a therapeutic window against cancer Seminars in Cancer Biology 2021 70 24 36 10.1016/j.semcancer.2020.06.009 32574811 · DOI
  148. [160]Azizian K. Pustokhina I. Ghanavati R. Hamblin M. R. Amini A. Kouhsari E. The potential use of theranostic bacteria in cancer Journal of Cellular Physiology 2021 236 6 4184 4194 10.1002/jcp.30152 33174198 · DOI
  149. [162]Kalia V. C. Patel S. K. S. Cho B. K. Wood T. K. Lee J. K. Emerging applications of bacteria as antitumor agents Seminars in Cancer Biology 2022 86 Pt 2 1014 1025 10.1016/j.semcancer.2021.05.012 33989734 · DOI
  150. [163]Roh J. S. Sohn D. H. Damage-associated molecular patterns in inflammatory diseases Immune network 2018 18 4 p. e27 10.4110/in.2018.18.e27 2-s2.0-85052882791 PMC6117512 30181915 · DOI · Paper page
  151. [164]Tahamtan A. Teymoori-Rad M. Nakstad B. Salimi V. Anti-inflammatory MicroRNAs and their potential for inflammatory diseases treatment Frontiers in Immunology 2018 9 1377 10.3389/fimmu.2018.01377 2-s2.0-85048961790 PMC6026627 29988529 · DOI
  152. [165]del Carmen S. Martín Rosique R. Saraiva T. Protective effects of lactococci strains delivering either IL-10 protein or cDNA in a TNBS-induced chronic colitis model Journal of Clinical Gastroenterology 2014 48 Supplement 1 S12 S17 10.1097/MCG.0000000000000235 2-s2.0-84916601452 25291117 · DOI
  153. [166]Ferenczi S. Solymosi N. Horváth I. Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria Molecular Therapy- Methods and Clinical Development 2021 20 218 226 10.1016/j.omtm.2020.11.010 33426148 PMC7782194 · DOI
  154. [167]Zahirović A. Berlec A. Targeting IL-6 by engineered Lactococcus lactis via surface-displayed affibody Microbial Cell Factories 2022 21 1 p. 143 10.1186/s12934-022-01873-7 PMC9287920 35842694 · DOI
  155. [168]Barra M. Danino T. Garrido D. Engineered probiotics for detection and treatment of inflammatory intestinal diseases Frontiers in Bioengineering and Biotechnology 2020 8 p. 265 10.3389/fbioe.2020.00265 PMC7137092 32296696 · DOI
  156. [169]Ko C. W. Singh S. Feuerstein J. D. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis Gastroenterology 2019 156 3 748 764 10.1053/j.gastro.2018.12.009 2-s2.0-85061005072 30576644 PMC6858922 · DOI
  157. [170]Oka A. Sartor R. B. Microbial-based and microbial-targeted therapies for inflammatory bowel diseases Digestive Diseases and Sciences 2020 65 3 757 788 10.1007/s10620-020-06090-z 32006212 PMC7311927 · DOI
  158. [171]Laurell A. Sjöberg K. Prebiotics and synbiotics in ulcerative colitis Scandinavian Journal of Gastroenterology 2017 52 4 477 485 10.1080/00365521.2016.1263680 2-s2.0-85010460623 27931127 · DOI
  159. [172]Sartor R. B. Wu G. D. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches Gastroenterology 2017 152 2 327 339.e4 10.1053/j.gastro.2016.10.012 2-s2.0-85007508333 27769810 PMC5511756 · DOI · Paper page
  160. [173]Álvarez B. Fernández L. Sustainable therapies by engineered bacteria Microbial Biotechnology 2017 10 5 1057 1061 10.1111/1751-7915.12778 2-s2.0-85023177674 28696008 PMC5609241 · DOI
  161. [174]Dosoky N. S. May-Zhang L. S. Davies S. S. Engineering the gut microbiota to treat chronic diseases Applied Microbiology and Biotechnology 2020 104 18 7657 7671 10.1007/s00253-020-10771-0 32696297 PMC7484268 · DOI
  162. [175]Steidler L. Hans W. Schotte L. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 Science 2000 289 5483 1352 1355 10.1126/science.289.5483.1352 2-s2.0-0034714188 10958782 · DOI · Paper page
  163. [176]Wei P. Yang Y. Ding Q. Oral delivery of Bifidobacterium longum expressing α-melanocyte-stimulating hormone to combat ulcerative colitis Journal of Medical Microbiology 2016 65 2 160 168 10.1099/jmm.0.000197 2-s2.0-84959257406 26567174 · DOI
  164. [177]Del Carmen S. De Moreno De LeBlanc A. Martin R. Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities Applied and Environmental Microbiology 2014 80 3 869 877 10.1128/aem.03296-13 2-s2.0-84892957370 24242245 PMC3911219 · DOI
  165. [178]Hillert A. Anikster Y. Belanger-Quintana A. The genetic landscape and epidemiology of phenylketonuria The American Journal of Human Genetics 2020 107 2 234 250 10.1016/j.ajhg.2020.06.006 32668217 PMC7413859 · DOI
  166. [179]Basarkar V. Govardhane S. Shende P. Multifaceted applications of genetically modified micro-organisms: a biotechnological revolution Current Pharmaceutical Design 2022 28 22 1833 1842 10.2174/1381612828666220128102823 35088657 · DOI
  167. [181]Stritzker J. Weibel S. Hill P. J. Oelschlaeger T. A. Goebel W. Szalay A. A. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice International Journal of Medical Microbiology 2007 297 3 151 162 10.1016/j.ijmm.2007.01.008 2-s2.0-34247618171 17448724 · DOI · Paper page
  168. [182]Sonnenborn U. Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties FEMS Microbiology Letters 2016 363 19 p. fnw212 10.1093/femsle/fnw212 2-s2.0-84992188321 27619890 · DOI · Paper page
  169. [183]Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease Inflammatory Bowel Diseases 2008 14 7 1012 1018 10.1002/ibd.20377 2-s2.0-47949120118 18240278 · DOI · Paper page
  170. [184]Mimee M. Tucker A. C. Voigt C. A. Lu T. K. Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota Cell Systems 2015 1 1 62 71 10.1016/j.cels.2015.06.001 2-s2.0-84938323503 26918244 PMC4762051 · DOI · Paper page
  171. [185]Yamada T. Hiraoka Y. Ikehata M. Apoptosis or growth arrest: modulation of tumor suppressor p53’s specificity by bacterial redox protein azurin Proceedings of the National Academy of Sciences of the United States of America 2004 101 14 4770 4775 10.1073/pnas.0400899101 2-s2.0-1842687879 15044691 PMC387323 · DOI · Paper page
  172. [188]Chowdhury S. Castro S. Coker C. Hinchliffe T. E. Arpaia N. Danino T. Programmable bacteria induce durable tumor regression and systemic antitumor immunity Nature Medicine 2019 25 7 1057 1063 10.1038/s41591-019-0498-z 2-s2.0-85068740692 PMC6688650 31270504 · DOI · Paper page
  173. [189]Nakamura T. Sasaki T. Fujimori M. Cloned cytosine deaminase gene expression of Bifidobacterium longum and application to enzyme/pro-drug therapy of hypoxic solid tumors Bioscience, Biotechnology, and Biochemistry 2002 66 11 2362 2366 10.1271/bbb.66.2362 2-s2.0-0037544973 12506973 · DOI
  174. [190]Yi C. Huang Y. Guo Z. Y. Wang S. R. Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantis on melanoma Acta Pharmacologica Sinica 2005 26 5 629 634 10.1111/j.1745-7254.2005.00094.x 2-s2.0-18844382645 15842785 · DOI · Paper page
  175. [191]Sun Y. Zheng J. H. Visualized cancer immunotherapy with engineered Salmonella typhimurium Methods in Molecular Biology 2022 2521 283 294 10.1007/978-1-0716-2441-8_15 35733004 · DOI
  176. [192]Kang M. Choe D. Kim K. Cho B. K. Cho S. Synthetic biology approaches in the development of engineered therapeutic microbes International Journal of Molecular Sciences 2020 21 22 p. 8744 10.3390/ijms21228744 PMC7699352 33228099 · DOI
  177. [193]Ruder W. C. Lu T. Collins J. J. Synthetic biology moving into the clinic Science (New York, NY) 2011 333 6047 1248 1252 10.1126/science.1206843 2-s2.0-80052484996 21885773 · DOI
  178. [194]Woo S. G. Moon S. J. Kim S. K. A designed whole-cell biosensor for live diagnosis of gut inflammation through nitrate sensing Biosensors and Bioelectronics 2020 168 112523 10.1016/j.bios.2020.112523 32871497 · DOI
  179. [196]Danino T. Prindle A. Kwong G. A. Programmable probiotics for detection of cancer in urine Science Translational Medicine 2015 7 289 p. 289ra84 10.1126/scitranslmed.aaa3519 2-s2.0-84930153477 PMC4511399 26019220 · DOI
  180. [198]Baumgart D. C. Sandborn W. J. Inflammatory bowel disease: clinical aspects and established and evolving therapies The Lancet 2007 369 9573 1641 1657 10.1016/s0140-6736(07)60751-x 2-s2.0-34248136340 17499606 · DOI
  181. [199]Wang X. Sherman A. Liao G. Mechanism of oral tolerance induction to therapeutic proteins Advanced Drug Delivery Reviews 2013 65 6 759 773 10.1016/j.addr.2012.10.013 2-s2.0-84878836808 23123293 PMC3578149 · DOI
  182. [200]Braat H. Rottiers P. Hommes D. W. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease Clinical Gastroenterology and Hepatology 2006 4 6 754 759 10.1016/j.cgh.2006.03.028 2-s2.0-33744933432 16716759 · DOI · Paper page
  183. [201]Mancha-Agresti P. Drumond M. M. Carmo F. L. A new broad range plasmid for DNA delivery in eukaryotic cells using lactic acid bacteria: in vitro and in vivo assays Molecular Therapy- Methods and Clinical Development 2017 4 83 91 10.1016/j.omtm.2016.12.005 2-s2.0-85015789025 28344994 PMC5363290 · DOI
  184. [202]Jacouton E. Torres Maravilla E. Boucard A. S. Anti-tumoral effects of recombinant Lactococcus lactis strain secreting IL-17a cytokine Frontiers in Microbiology 2018 9 p. 3355 10.3389/fmicb.2018.03355 2-s2.0-85064412732 PMC6351453 30728820 · DOI
  185. [203]Shigemori S. Watanabe T. Kudoh K. Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice Microbial Cell Factories 2015 14 1 p. 189 10.1186/s12934-015-0378-2 2-s2.0-84961185950 PMC4658813 26608030 · DOI
  186. [204]Caluwaerts S. Vandenbroucke K. Steidler L. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis Oral Oncology 2010 46 7 564 570 10.1016/j.oraloncology.2010.04.008 2-s2.0-77953359952 20542722 · DOI
  187. [205]Chen H. L. Lai Y. W. Chen C. S. Probiotic Lactobacillus casei expressing human lactoferrin elevates antibacterial activity in the gastrointestinal tract Biometals 2010 23 3 543 554 10.1007/s10534-010-9298-0 2-s2.0-77953289731 20148305 · DOI
  188. [206]Huibregtse I. L. Snoeck V. de Creus A. Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin Gastroenterology 2007 133 2 517 528 10.1053/j.gastro.2007.04.073 2-s2.0-34547503872 17681173 · DOI
  189. [207]Daniel C. Sebbane F. Poiret S. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV Vaccine 2009 27 8 1141 1144 10.1016/j.vaccine.2008.12.022 2-s2.0-59049095067 19135495 · DOI
  190. [208]Lei H. Peng X. Jiao H. Zhao D. Ouyang J. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice Microbial Cell Factories 2015 14 1 p. 111 10.1186/s12934-015-0287-4 2-s2.0-84939435743 PMC4524015 26242406 · DOI
  191. [209]Vandenbroucke K. de Haard H. Beirnaert E. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis Mucosal Immunology 2010 3 1 49 56 10.1038/mi.2009.116 2-s2.0-77249133143 19794409 · DOI
  192. [210]Robert S. Gysemans C. Takiishi T. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice Diabetes 2014 63 8 2876 2887 10.2337/db13-1236 2-s2.0-84905003513 24677716 · DOI
  193. [211]Egeland T. A. Gaustad J. V. Galappathi K. Rofstad E. K. Magnetic resonance imaging of tumor necrosis Acta Oncologica 2011 50 3 427 434 10.3109/0284186x.2010.526633 2-s2.0-79952675402 20950229 · DOI
  194. [215]Robinson C. J. Carbonell P. Jervis A. J. Rapid prototyping of microbial production strains for the biomanufacture of potential materials monomers Metabolic Engineering 2020 60 168 182 10.1016/j.ymben.2020.04.008 32335188 PMC7225752 · DOI
  195. [216]Ghanavati R. Akbari A. Mohammadi F. Lactobacillus species inhibitory effect on colorectal cancer progression through modulating the Wnt/β-catenin signaling pathway Molecular and Cellular Biochemistry 2020 470 1-2 1 13 10.1007/s11010-020-03740-8 32419125 · DOI
  196. [217]Biller B. J. Dow S. Withrow S. J. Vail D. M. Chapter 13- immunotherapy of cancer Withrow & MacEwen’s Small Animal Clinical Oncology 2007 4th Saint Louis, MO, USA W.B. Saunders 211 235
  197. [218]Parisa A. Roya G. Mahdi R. Shabnam R. Maryam E. Malihe T. Anti-cancer effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis PLoS One 2020 15 5 e0232930 10.1371/journal.pone.0232930 PMC7219778 32401801 · DOI
  198. [219]Tahamtan A. Teymoori-Rad M. Nakstad B. Salimi V. Anti-inflammatory MicroRNAs and their potential for inflammatory diseases treatment Frontiers in Immunology 2018 9 p. 1377 10.3389/fimmu.2018.01377 2-s2.0-85048961790 PMC6026627 29988529 · DOI
  199. [220]Ferenczi S. Solymosi N. Horváth I. Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria Molecular Therapy-Methods and Clinical Development 2021 20 218 226 10.1016/j.omtm.2020.11.010 33426148 PMC7782194 · DOI
  200. [221]Ko C. W. Singh S. Feuerstein J. D. AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis Gastroenterology 2019 156 3 748 764 10.1053/j.gastro.2018.12.009 2-s2.0-85061005072 30576644 PMC6858922 · DOI

200 of 287 shown

Authors
Mahdizade Ari, M., Dadgar, L., Elahi, Z., Ghanavati, R., & Taheri, B.
Affiliations
  • Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Iran University of Medical Sciences (IR)
  • Behbahan Faculty of Medical Sciences, Behbahan, Iran
  • Ahvaz Jundishapur University of Medical Sciences (IR)
Corresponding author
  • Ghanavati, Roya
  • Taheri, Behrouz
ORCID
Venue
International Journal of Clinical Practice
Publisher
Wiley
Published
2024-03-09
Volume
2024
Pages
1-38
ISSN
  • 1368-5031 (ISSN-L)
  • 1742-1241
DOI
10.1155/2024/6638269
PMC
PMC10944348
OpenAlex
W4392622957
Cited by
67
References
20
Citations by year
2026: 23 · 2025: 33 · 2024: 11
FWCI
2.82
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Clinical Practice (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Behbahan Faculty of Medical Sciences (401084)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Microbial Metabolic Engineering and Bioproduction
  • Physical Sciences › Environmental Science › Ecology › Bacteriophages and microbial interactions
Keywords
genetically modified microorganisms, engineered bacteria, antibiotic resistance, synthetic biology, drug delivery, cancer therapy, metabolic disorders, inflammatory diseases, biosynthesis, route of administration, environmental impact, human health
MeSH terms
Anti-Bacterial Agents, Bacteria, Drug Resistance, Microbial, Genetic Engineering, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review